Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

In a new Oxford Science Blog, Dr Pavandeep Rai (Department of Physiology, Anatomy and Genetics) guides us through her career and experiences of pushing the boundaries of science in both research and art.

Hard at work in the lab, Pavandeep works to unlock the secrets of Parkinson's

Dr Pavandeep Rai is a Post-doctoral Research Scientist in the Department of Physiology, Anatomy and Genetics. Her work focuses on the effect of something called 'mitochondria' on Parkinson's disease, using cutting edge gene-editing cool CRISPR-Cas. 

To start with, can you give us a beginner’s guide to your research? What is ‘mitochondria drug discovery’?

I started my ‘love affair’ with mitochondria during my undergrad degree at Birmingham, particularly in my year in industry with AstraZeneca. Basically, mitochondria are organelles, small entities within our cells. Their main job is to make something called ATP, which is the energy our cells use. So, if something goes wrong or your mitochondria start to degrade, then that will reduce the amount of energy and your cells don’t work as well.

The lab I’m working in looks specifically at Parkinson’s disease. By looking at the mitochondria, we can try to find ways to improve their functionality. Can we stop them from degrading? Once they’ve started, can we stop them from getting worse?

Currently, I’m using genetic editing tool called CRISPR-Cas. It’s been in the news recently, you might have seen those stories about ‘designer babies’ and the like? But we use it as a research tool to see how removing genes from the genome affects mitochondria.

If we remove a gene and it improves function, then we could maybe use it as a treatment for Parkinson’s.

If removing a gene decreases function in healthy cells, then that tells us something else. Perhaps this is one of the ways that the disease itself progresses?

So, it ties into two aspects of research: one is treatment and the other is understanding.

Read more on the Oxford Science Blog website

Similar stories

Human challenge trial launches to study immune response to COVID-19

Clinical Trials Coronavirus COVID-19 General

Though the COVID-19 pandemic has now been active for a year, not much is known about what happens when people who have already had COVID-19 are infected for a second time.

Risk of rare blood clotting higher for COVID-19 than for vaccines

Coronavirus COVID-19 Research

COVID-19 leads to a several-times higher risk of cerebral venous thrombosis (CVT) blood clots than current COVID-19 vaccines.

Alternating vaccines trial expands to include two additional vaccines

Clinical Trials Coronavirus COVID-19 General

Researchers running the Com-Cov study, launched in February to investigate alternating doses of the Oxford-AstraZeneca vaccine and the Pfizer vaccine, have today announced that the programme will be extended to include the Moderna and Novavax vaccines in a new study.

Oxford medical students launch flagship raffle in aid of NHS heroes and lifesaving medical equipment

General

Tingewick, a society formed of medical students from Oxford University, are hosting a virtual charity raffle. With over 70 amazing prizes, ranging from Truck festival tickets to restaurant vouchers to bags of books and even a bike, the raffle is an exciting way to celebrate lockdown lifting by supporting many wonderful Oxfordshire businesses whilst raising lots of money for charity.

Asthma drug budesonide shortens recovery time in non-hospitalised patients with COVID-19

Clinical Trials Coronavirus COVID-19 Research

Inhaled budesonide, a common corticosteroid, is the first widely available, inexpensive drug found to shorten recovery times in COVID-19 patients aged over 50 who are treated at home and in other community settings, reports the PRINCIPLE trial in 1,779 participants.

UK and EU regulators conclude benefits of vaccination continue to outweigh the risks

Coronavirus COVID-19 General

Today, the medical regulators in the UK and Europe have announced their conclusions from their reviews of very rare cases of unusual blood clots in people who have received the Oxford-AstraZeneca coronavirus vaccine.